secwatch.observer — SEC 8-K summary
======================================

Issuer:     Quoin Pharmaceuticals, Ltd. (QNRX)
CIK:        0001671502
Form:       8-K
Filed at:   2026-06-04T20:04:26+00:00
Accession:  0001104659-26-070501
Event type: regulatory
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Quoin Pharma gets Japan MHLW Orphan Drug Designation for QRX003 in Netherton Syndrome
--------------------------------------------------------------------------------

- Japan MHLW granted Orphan Drug Designation to QRX003 lotion (4%) for Netherton Syndrome, a rare genetic skin disorder with no approved treatments.
- Designation provides incentives including up to 10 years of market exclusivity upon approval, priority review, and tax breaks.
- Adds to prior U.S. FDA Orphan Drug, Pediatric Rare Disease, and Fast Track designations, plus EMA Orphan Drug Designation.
- Quoin plans to self-commercialize QRX003 in Japan, U.S., and Western Europe; pivotal Phase 3 study expected H2 2026, NDA filing in 2027.
- Company working with Japanese clinicians to refine clinical/regulatory pathway for approval.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1671502/000110465926070501/0001104659-26-070501-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1671502/000110465926070501/tm2616916d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-070501

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer